Covidien plc VP Buys $359,078 in Stock (COV)
Covidien plc (NYSE:COV) VP Coleman N. Lannum III acquired 4,100 shares of the company’s stock in a transaction dated Monday, August 18th. The stock was purchased at an average price of $87.58 per share, for a total transaction of $359,078.00. Following the completion of the purchase, the vice president now directly owns 11,042 shares of the company’s stock, valued at approximately $967,058. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of Covidien plc (NYSE:COV) traded up 0.55% on Thursday, hitting $89.28. The stock had a trading volume of 280,642 shares. Covidien plc has a one year low of $59.17 and a one year high of $92.68. The stock has a 50-day moving average of $88. and a 200-day moving average of $77.01. The company has a market cap of $40.333 billion and a price-to-earnings ratio of 26.78. Covidien plc also was the recipient of a significant increase in short interest in July. As of July 31st, there was short interest totalling 4,958,375 shares, an increase of 84.5% from the July 15th total of 2,686,967 shares. Based on an average trading volume of 5,915,966 shares, the days-to-cover ratio is currently 0.8 days. Currently, 1.1% of the company’s stock are short sold.
Covidien plc (NYSE:COV) last announced its earnings results on Friday, July 25th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.04. The company had revenue of $2.69 billion for the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter in the previous year, the company posted $0.91 earnings per share. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. Analysts expect that Covidien plc will post $4.02 EPS for the current fiscal year.
COV has been the subject of a number of recent research reports. Analysts at Citigroup Inc. reiterated a “buy” rating on shares of Covidien plc in a research note on Monday, July 28th. They now have a $101.00 price target on the stock, up previously from $81.00. Separately, analysts at Leerink Swann raised their price target on shares of Covidien plc from $93.00 to $95.00 in a research note on Monday, July 28th. They now have a “market perform” rating on the stock. Finally, analysts at RBC Capital raised their price target on shares of Covidien plc from $71.00 to $95.00 in a research note on Monday, July 28th. Eleven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $87.54.
Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings.
Receive News & Ratings for Covidien plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covidien plc and related companies with Analyst Ratings Network's FREE daily email newsletter.